The U.S. Supreme Court’s May 2023 decision in Amgen, Inc. v. Sanofi (Amgen) sent shock waves through the patent world, particularly in the chemical and biotech segments, due to its invalidation of Amgen patents based on a...more
1/19/2024
/ Amgen v Sanofi ,
Biosimilars ,
Biotechnology ,
Genus ,
Inventions ,
New Guidance ,
Patent Examinations ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Popular ,
SCOTUS ,
Utility Patents